Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 10/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.53 |
| ▸ | STK4 | Q13043 | 5/20 | 0.50 |
| ▸ | IGF1R | P08069 | 3/20 | 0.50 |
| ▸ | STK3 | Q13188 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203293 | 0.94 | MAP2K1 (0.59) | MAP2K1EGFRERBB2STK4IGF1R | |
| SCHEMBL2205626 | 0.88 | MAP2K1 (0.62) | MAP2K1EGFRERBB2STK4IGF1R | |
| SCHEMBL6379609 | 0.82 | EGFR (0.78) | MAP2K1EGFRERBB2STK4STK3 | |
| SCHEMBL6999694 | 0.81 | MAP2K1 (0.52) | MAP2K1EGFRERBB2STK4IGF1R | |
| SCHEMBL6995272 | 0.81 | MAP2K1 (0.50) | MAP2K1EGFRERBB2STK4IGF1R | |
| Hydrochloric Acid SCHEMBL6385742 | 0.81 | EGFR (0.77) | MAP2K1EGFRERBB2STK4STK3 | |
| SCHEMBL2203726 | 0.81 | MAP2K1 (0.63) | MAP2K1EGFRERBB2STK4IGF1R | |
| SCHEMBL2204131 | 0.80 | EGFR (0.77) | MAP2K1EGFRERBB2STK4STK3 | |
| SCHEMBL2204137 | 0.80 | EGFR (0.77) | MAP2K1EGFRERBB2STK4STK3 | |
| SCHEMBL2200289 | 0.79 | EGFR (0.64) | MAP2K1EGFRERBB2STK4STK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117659-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH CORP (US) | 2003-12-03 | — | — | EP | claimed |
| US-6288082-B1 | COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | claimed |
| EP-1117659-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018761-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| US-7982043-B2 | Protein tyrosine kinase enzyme inhibitors | WYETH LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| US-20080319011-A1 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-7399865-B2 | such as (E)-N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide used as antineoplastic agents, or inhibitors of the HER-2 gene or proteins and epidermal growth factor receptor enzymes | WYETH (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1670473-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005034955-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005028443-A2 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH A CORPORATION OF THE STATE OF DELAWARE, USA (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | WYETH (US) | 2005-03-17 | — | — | US | disclosed |
| EP-1119551-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000020389-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319011-A1 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | ABL1, ERBB2, RET | MAP2K1 602/4885EGFR 6/4885ERBB2 2/4885 |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | ABL1, ERBB2, RET | MAP2K1 602/4885EGFR 6/4885ERBB2 2/4885 |
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | FASN, FRS2, FGFR1 | MAP2K1 840/4885EGFR 20/4885ERBB2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.